Orforglipron and Carbamazepine Drug-Drug Interaction Study in Healthy Participants

Phase 1, open-label, single-arm trial of orforglipron in type 2 diabetes mellitus (T2DM) and obesity, sponsored by Eli Lilly and Company. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to Infinity of Orforglipron at Day 15, Area Under the Concentration Versus Time Curve From Time Zero to the Last Measurable Concentration of Orforglipron at Day 15 and 1 more. Started May 2024; status: completed.